ELMD
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Electromed, Inc. develops, manufactures, and markets airway clearance therapy products, primarily the SmartVest Airway Clearance System, which utilizes High Frequency Chest Wall Oscillation (HFCWO) to clear secretions from the lungs and airways. The company serves patients with compromised pulmonary function, including those with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis. Electromed employs a direct-to-patient and provider model, managing insurance claims and delivering devices to patients for home use, while also selling into acute care settings for post-surgical or intensive care patients. The product portfolio includes the SmartVest SQL and the next-generation SmartVest Clearway, both featuring programmable air pulse generators and therapy garments. Additional products include the Single Patient Use SmartVest and SmartVest Wrap for hospital use. The company provides patient education, training, and reimbursement support services. Electromed was incorporated in 1992 and has marketed its HFCWO devices since 2000. The company is approved for device sales in the United States and select international markets.

Summarised from the company's own disclosures, fiscal year ended Aug 2026

Industry Medical Devices Homepage smartvest.com
Sector Healthcare IR page investors.smartvest.com/overview/default.aspx
Tags
airway clearance, high frequency chest wall oscillation, pulmonary therapy, home medical equipment, respiratory care, bronchiectasis, cystic fibrosis, neuromuscular disorders, medical devices, patient support services, SmartVest, SmartVest SQL, SmartVest Clearway, SmartVest Wrap, Single Patient Use SmartVest, Soft Start, Breathing Room, SmartVest Connect
Press page —

Metrics

Valuation  
Market cap $ 232.519M
Market cap (USD) $ 232.519M
P/E 20.61
PEG 0.39
P/BV 4.43
P/S 3.08
P/OCF 23.56
P/FCF 26.71
Dividend yield —
Turnover / mcap —
Returns  
ROE 23.3%
ROI 20.9%
ROIC 20.2%
Profit margin 15.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 52.8%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score 41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009
Revenue 73.776M 64M 54.716M 48.067M 41.659M 35.756M 32.471M 31.3M 28.698M 25.861M 22.992M 19.408M 15.488M 15.104M 19.524M 19.004M 12.999M
Net profit 11.301M 7.537M 5.15M 3.166M 2.305M 2.362M 4.161M 1.969M 1.902M 2.229M 2.213M 1.092M -1.289M -1.329M 186.606K 1.056M 1.355M
Free cash flow 8.413M 11.131M 8.78M -333K -2.111M 2.79M 3.352M 1.259M 1.916M 572.358K 1.632M 2.258M 1.167M 860.033K -1.963M -1.881M -1.806M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009
Share price 42.3 21.99 15.03 10.71 9.64 11.29 15.39 5.45 5.42 5.53 3.86 1.85 1.43 1.27 2.65 3 —
Price performance 12m 0.92 0.46 0.4 0.11 -0.15 -0.27 1.82 0.01 -0.02 0.43 1.08 0.29 0.13 -0.52 -0.12 — —

Filed figures

Figure Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 9.95M 11.6M 12.8M 12.9M 17M 21.1M 24.1M 23.3M 24.7M 29.8M
↳ YoY growth +30.7% +16.2% +10.4% +1.4% +31.6% +23.6% +14.6% -3.3% +5.7% +20.9%
↳ 5y CAGR -1.7% +5.1% +14.5% +14.7% +17.5% +16.2% +15.8% +12.8% +13.8% +11.8%
Borrowings, current (USD) 50,703 1.1M 30,320 72,328 33,000 — — — — —
Borrowings, non-current (USD) 1.1M — — — — — — — — —
Lease liabilities (USD) — — 45,000 81,000 87,000 120,000 161,000 87,000 198,000 133,000
Cash and deposits (USD) — — — 10.5M 11.9M 8.15M 7.37M 16.1M 15.3M 20.5M
Intangible assets (USD) 721,276 649,103 581,413 598,389 663,000 599,000 605,000 657,000 371,000 379,000
Right-of-use assets (USD) — — 45,000 80,000 88,000 120,000 — 87,000 198,000 131,000
Net debt (borrowings + leases - cash) (USD) — — — -10.4M -11.8M — — — — —
Cash flow detail
Operating cash flow (USD) 1.19M 2.44M 2.59M 4.2M 3.08M -686,000 1.32M 9.07M 11.4M 9.67M
Purchases of property, plant and equipment (USD) -618,763 -526,227 -1.33M -844,226 -287,000 -1.43M -1.65M -287,000 -262,000 -1.25M
Purchases of intangible assets (USD) -68,385 -45,550 -57,790 -132,970 -161,000 -100,000 -68,000 -108,000 -44,000 -48,000
Change in receivables (cash effect) (USD) -2.34M -1.61M -948,734 -180,635 -4.09M -4.02M -3.08M 797,000 -1.33M -5.15M
Change in inventories (cash effect) (USD) -28,334 234,594 -106,174 -449,335 971,000 -1.07M -1.03M 459,000 175,000 -517,000
Change in payables (cash effect) (USD) -337,470 555,992 -2,564 -472,589 1.28M 2.17M 420,000 -1.21M 1.65M 652,000
Share buybacks (cash effect) (USD) — — — — -1.12M -1.45M -153,000 -275,000 -10M -3.92M
Interest paid (cash effect) (USD) -59,233 -46,002 -22,991 -3,133 — — — — — —
Income taxes paid (cash effect) (USD) -1.09M -1.02M -1.31M -1.75M -534,000 77,000 310,000 -2.51M -3.74M -3.39M
Share-based compensation (USD) 479,482 862,674 924,071 901,932 1.02M 976,000 708,000 1.69M 3.06M 2.72M
Operating cash flow before change in receivables (USD) 3.53M 4.06M 3.54M 4.38M 7.17M 3.33M 4.39M 8.27M 12.7M 14.8M
Free cash flow (OCF - PPE - intangibles) (USD) 503,973 1.87M 1.2M 3.22M 2.63M -2.21M -401,000 8.67M 11.1M 8.37M
Income detail
Research and development expense (USD) 596,876 251,443 583,311 1.05M 1.72M 1.36M 916,000 656,000 996,000 1.31M
↳ 5y CAGR -8.3% -16.1% +4.6% +27.2% +35.3% +17.8% +29.5% +2.4% -1.0% -5.3%
Provision for credit losses (USD) — — — — — — — — 0.00 0.00
Credit cost ratio (credit losses / average receivables) (%) — — — — — — — — 0.0% 0.0%
Reported Sep 5, 2017 Sep 25, 2018 Nov 12, 2019 Aug 24, 2021 Aug 24, 2021 Aug 23, 2022 Aug 22, 2023 Aug 26, 2025 Aug 25, 2026 Aug 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Electromed, Inc. — Current report on Form 8-K Bull 0 Bear 0 Routine

Submission of Matters to a Vote of Security Holders.

At the annual meeting of shareholders of Electromed, Inc. (the “Company”) held on November 13, 2026, the following proposals, each as described in further detail in the definitive proxy statement filed on September 29, 2026, were voted upon by our shareholders as set forth below:

1. The following individuals designated by our Board of Directors ("Board") as nominees for director were elected for a one-year term or until a successor has been elected and qualified, thereby setting the number of directors at seven, with voting as follows:

Name For Withheld Broker Non-Votes

James L. Cunniff 4,943,959 71,507 1,563,582

Stan K. Erickson 4,908,618 106,848 1,563,582 Gregory J. Fluet 4,561,739 453,727 1,563,582 Joseph L. Galatowitsch 4,955,310 60,156 1,563,582 Kathleen S. Skarvan 3,369,973 1,645,493 1,563,582 Kathleen A. Tune 4,953,163 62,303 1,563,582 Andrea M. Walsh 4,949,906 65,560 1,563,582

2. Our shareholders ratified the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2027, with voting as follows:

For Against Abstain

6,544,291 22,740 12,017

3.

16th consecutive quarter of year-over-year revenue and operating income growth

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2026 (“Q1 FY 2027”).

Q1 FY 2027 Company Highlights

• Net revenues were $18.7 million in Q1 FY 2027, a 10.6% increase from $16.9 million in the first quarter of the prior fiscal year, driven by a 17.6% increase in the core homecare market.

• Operating income increased to $3.5 million, a 30.7% increase from the first quarter of the prior fiscal year, and 18.7% of net revenues.

• Net income was $2.8 million, or $0.32 per diluted share, representing an increase of 29.3%, compared to $2.1 million, or $0.25 per diluted share in the first quarter of the prior fiscal year.

“We delivered our 16th consecutive quarter of year-over-year revenue and operating income growth, with double-digit revenue growth, a 30.7% increase in operating income and an 80.0% gross margin—demonstrating the strength of our direct-to-patient model and operating leverage.

10/27/2026

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2027 first quarter ended September 30, 2026, on Tuesday, November 10, 2026, after the close of the stock market. Company management will host a conference call on the same day at 5:00 p.m. Eastern Time to discuss the results.

Interested parties may participate in the call by dialing (877) 407-3982 (Toll Free) or (201) 493-6780.

The live webcast of the call will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: Electromed's Q1 Fiscal 2027 Earnings Call

For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Toll Free) or (412) 317-6671 and referencing Access ID 13763053. Additionally, a replay of the webcast will be available in the Investor Relations section of Electromed’s web site at: Events & Presentations

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com .

Source: Electromed, Inc.

Brad Nagel, Chief Financial Officer
(952) 758-9299
[email protected]

Mike Cavanaugh, Investor Relations
ICR Healthcare
(617) 877-9641
[email protected]

Source: Electromed, Inc.

View All News

Contact Us

Mike Cavanaugh
ICR Healthcare

[email protected]

“SmartVest,” "Clearway," “SQL,” "SmartVest Connect," “SmartVest Wrap,” and “Making life’s important moments possible—one breath at a time” are registered trademarks of Electromed, Inc. Any other trademarks cited are the property of their respective owners.

Quick Links

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Electromed, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Electromed, Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

News
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote
Events & Presentations

Submit Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

Request a Meeting With Management >

placeholder company

Copyright © 2026 Electromed, Inc. All rights reserved.

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Prompts

Electromed, Inc. (ticker ELMD), listed in United States.

ETFs Holding Electromed, Inc.

ETF Weight in ETF Shares Market value As of
SQLV 0.26% 1,761 $ 74.49K Jun 30, 2026
FSEG 0.13% 172 $ 7,275.60 Jun 30, 2026
AVSC 0.01% 13,155 $ 303.881K Nov 16, 2026
DFAS 0.01% 71,443 $ 1.784M Nov 12, 2026
DXUV 0.00% 4,320 $ 107.87K Nov 12, 2026
DFAC 0.00% 20,656 $ 515.78K Nov 12, 2026
DCOR 0.00% 6,183 $ 154.39K Nov 12, 2026
DFUS 0.00% 1,107 $ 27.642K Nov 12, 2026
DFSU 0.00% 4 $ 99.88 Nov 12, 2026
AVUS 0.00% 436 $ 10.072K Nov 16, 2026